Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Updated PXD101 phase I results presented at the AACR-EORTC-NCI conference
December 22nd, 2005
CuraGen Corp. (CRGN) and TopoTarget, A/S, (TOPO) announced updated interim phase I data on PXD101, a small-molecule histone deacetylase inhibitor being developed for the treatment of solid and hematologic tumors, were presented at the American Association for Cancer Research-U.S. National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics. In a poster entitled "A Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) study of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Patients with Advanced Solid Tumors," interim data on 42 patients receiving PXD101 as...
Source: Women's Health Weekly (2005-12-22)
|
